Pulsenmore

Pulsenmore (NASDAQ and TASE: PLSM) is a global leader in connected, home-based ultrasound technology, bringing clinical-grade imaging and guided care into the patient’s home. Our telehealth prenatal care platform enables expectant mothers to perform physician-prescribed ultrasound scans remotely, with results reviewed by clinicians as part of an integrated care pathway. This model expands access to care, helps health systems use clinical resources more efficiently, and gives patients and caregivers more flexibility without compromising oversight.
Pulsenmore is the only FDA-Authorized Home Ultrasound. It's approved for commercial use in the U.S., Europe, the UK, Switzerland, Australia, Brazil, Colombia, and Israel.

Beyond prenatal care, our product roadmap includes at-home follicular monitoring for IVF patients, designed to reduce clinic visits while maintaining medical supervision throughout the cycle.

Pulsenmore’s vision is to make ultrasound imaging more accessible and intuitive, extending care beyond the clinic to improve outcomes and support equity in women’s health globally.